全文获取类型
收费全文 | 2944篇 |
免费 | 267篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 194篇 |
妇产科学 | 42篇 |
基础医学 | 381篇 |
口腔科学 | 118篇 |
临床医学 | 265篇 |
内科学 | 521篇 |
皮肤病学 | 93篇 |
神经病学 | 157篇 |
特种医学 | 335篇 |
外国民族医学 | 1篇 |
外科学 | 399篇 |
综合类 | 45篇 |
预防医学 | 322篇 |
眼科学 | 47篇 |
药学 | 128篇 |
中国医学 | 9篇 |
肿瘤学 | 163篇 |
出版年
2023年 | 22篇 |
2022年 | 27篇 |
2021年 | 44篇 |
2020年 | 31篇 |
2019年 | 35篇 |
2018年 | 76篇 |
2017年 | 66篇 |
2016年 | 66篇 |
2015年 | 95篇 |
2014年 | 119篇 |
2013年 | 163篇 |
2012年 | 141篇 |
2011年 | 127篇 |
2010年 | 140篇 |
2009年 | 156篇 |
2008年 | 106篇 |
2007年 | 153篇 |
2006年 | 125篇 |
2005年 | 80篇 |
2004年 | 93篇 |
2003年 | 55篇 |
2002年 | 66篇 |
2001年 | 69篇 |
2000年 | 63篇 |
1999年 | 62篇 |
1998年 | 116篇 |
1997年 | 112篇 |
1996年 | 115篇 |
1995年 | 71篇 |
1994年 | 85篇 |
1993年 | 49篇 |
1992年 | 40篇 |
1991年 | 30篇 |
1990年 | 28篇 |
1989年 | 41篇 |
1988年 | 36篇 |
1987年 | 42篇 |
1986年 | 46篇 |
1985年 | 38篇 |
1984年 | 22篇 |
1983年 | 18篇 |
1982年 | 31篇 |
1981年 | 18篇 |
1980年 | 20篇 |
1979年 | 14篇 |
1978年 | 11篇 |
1977年 | 17篇 |
1976年 | 16篇 |
1975年 | 12篇 |
1974年 | 7篇 |
排序方式: 共有3240条查询结果,搜索用时 15 毫秒
81.
BD White A Kong E Khoo AM Southcott 《Journal of Medical Imaging and Radiation Oncology》2005,49(4):319-321
Tracheobronchopathia osteochondroplastica (TO) is a rare benign disease characterized by the presence of osseous and cartilaginous submucosal nodules projecting into the tracheobronchial tree. Most cases are asymptomatic and discovered incidentally at post‐mortem. We identified a case of TO on thoracic spiral CT and confirmed the diagnosis on bronchoscopy. This article reviews the imaging characteristics of TO, and shows the 3‐D virtual bronchoscopic and multiplanar reconstruction appearances of TO. 相似文献
82.
83.
84.
Adipokines played a limited role in predicting temporary growth differences between very low birthweight infants with and without bronchopulmonary dysplasia
下载免费PDF全文
![点击此处可从《Acta paediatrica (Oslo, Norway : 1992)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
85.
Niek Hugen MD Jasper J. P. van Beek BSc Johannes H. W. de Wilt MD Iris D. Nagtegaal MD 《Annals of surgical oncology》2014,21(9):2963-2970
The prognostic impact of mucinous carcinoma (MC) in colorectal cancer (CRC) has been subject to debate ever since the introduction of the classification of tumors according to their histological differentiation. MC is a distinct clinical and pathological entity within the spectrum of CRC and accounts for approximately 10–15 % of cases. Factors involved in MC development have not been completely understood, but clinical observations may lead to a better insight into the etiology of MC. In this article, we provide an in-depth review of the literature regarding etiological aspects of MC. We show that there are worldwide differences in the prevalence of MC, with low rates in Asian countries and higher rates in the western world. Moreover, MC is more commonly diagnosed in patients suffering from inflammatory bowel diseases or Lynch syndrome and an increased rate of MC is observed in patients with radiotherapy-induced CRCs. These findings are suggestive of a different oncogenic development. Identification of conditions that are associated with MC generates insight into the etiological pathways leading to the development of this special subtype. 相似文献
86.
Martha T. van der Beek Eric C.J. Claas Caroline S. van der Blij-de Brouwer Florence Morfin Lisette G. Rusman Aloys C.M. Kroes Ann C.T.M. Vossen 《Journal of clinical virology》2013,56(1):19-24
BackgroundSusceptibility testing of herpes simplex virus type 1 (HSV-1) is traditionally performed by a plaque reduction assay (PRA), but this is labor intensive, time consuming and has a manual read out.ObjectivesThe goal of this study was to develop an internally controlled real time PCR-based phenotypical susceptibility test for HSV-1 that is suitable for use in a clinical diagnostic setting.Study designA DNA reduction assay (DRA) was developed and validated on a test panel of 26 well-characterized isolates of varying susceptibility to aciclovir or foscarnet, including low-level resistant isolates. The DRA consisted of pre-culture of a clinical sample for 48 h and subsequent culture in the presence of antivirals for 24 h. Viral DNA concentration in the culture lysates was measured by an internally controlled quantitative real-time HSV-1 PCR and corrected for cell count and lysis by beta-globin PCR. DRA results were compared to results from PRA and sequence analysis.ResultsDRA results were in accordance with PRA results for both aciclovir and foscarnet susceptibility and appeared to have good discriminative value for low-level resistance due to UL30 gene mutations. Although the direct application of DRA in clinical samples appeared not possible, short pre-culture of 48 h was sufficient and ensured results within a clinically relevant time frame of 5 days.ConclusionsDRA is an accurate, rapid and easy to perform phenotypical susceptibility test for HSV-1. 相似文献
87.
88.
R.J. van de Peppel M.T. van der Beek L.G. Visser M.G.J. de Boer J. Wallinga 《International journal of antimicrobial agents》2019,53(3):284-293
Objectives
Triazole resistance in Aspergillus spp. is emerging and complicates prophylaxis and treatment of invasive aspergillosis (IA) worldwide. New polymerase chain reaction (PCR) tests on broncho-alveolar lavage (BAL) fluid allow for detection of triazole resistance at a genetic level, which has opened up new possibilities for targeted therapy. In the absence of clinical trials, a modelling study delivers estimates of the added value of resistance detection with PCR, and which empiric therapy would be optimal when local resistance rates are known.Design
A decision-analytic modelling study was performed based on epidemiological data of IA, extended with estimated dynamics of resistance rates and treatment effectiveness. Six clinical strategies were compared that differ in use of PCR diagnostics (used vs not used) and in empiric therapeutic choice in case of unknown triazole susceptibility: voriconazole, liposomal amphotericin B (LAmB) or both. Outcome measures were proportion of correct treatment, survival and serious adverse events.Results
Implementing aspergillus PCR tests was projected to result in residual treatment-susceptibility mismatches of <5% for a triazole resistance rate up to 20% (using voriconazole). Empiric LAmB outperformed voriconazole at resistance rates >5–20%, depending on PCR use and estimated survival benefits of voriconazole over LAmB. Combination therapy of voriconazole and LAmB performed best at all resistance rates, but the advantage over the other strategies should be weighed against the expected increased number of drug-related serious adverse events. The advantage of combination therapy over LAmB monotherapy became smaller at higher triazole resistance rates.Conclusions
Introduction of current aspergillus PCR tests on BAL fluid is an effective way to increase the proportion of patients that receive targeted therapy for IA. The results indicate that close monitoring of background resistance rates and adverse drug events are important to attain the potential benefits of LAmB. The choice of strategy ultimately depends on the probability of triazole resistance, the availability of PCR and individual patient characteristics. 相似文献89.
90.
Ellen Strijbos Martijn R. Tannemaat Iris Alleman Robert H.P. de Meel Jaap A. Bakker Ruud van Beek Frank P. Kroon Guus F. Rimmelzwaan Jan J.G.M. Verschuuren 《Vaccine》2019,37(7):919-925